Show simple item record

Prevalence of diffuse pancreatic beta islet cell disease with hyperinsulinism: Problems in recognition and management

dc.contributor.authorFajans, Stefan S.en_US
dc.contributor.authorThompson, Norman W.en_US
dc.contributor.authorFloyd, Jr. , John C.en_US
dc.contributor.authorCohen, Cynthiaen_US
dc.contributor.authorHarrison, Timothy S.en_US
dc.contributor.authorRasbach, Dennis A.en_US
dc.contributor.authorSanten, Richard J.en_US
dc.date.accessioned2006-09-08T19:07:26Z
dc.date.available2006-09-08T19:07:26Z
dc.date.issued1984-08en_US
dc.identifier.citationHarrison, Timothy S.; Fajans, Stefan S.; Floyd, John C.; Thompson, Norman W.; Rasbach, Dennis A.; Santen, Richard J.; Cohen, Cynthia; (1984). "Prevalence of diffuse pancreatic beta islet cell disease with hyperinsulinism: Problems in recognition and management." World Journal of Surgery 8(4): 583-587. <http://hdl.handle.net/2027.42/41314>en_US
dc.identifier.issn1432-2323en_US
dc.identifier.issn0364-2313en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/41314
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=6148809&dopt=citationen_US
dc.description.abstractAmong 77 patients with endogenous hyperinsulinism seen in 2 medical centers, diffuse islet cell disease accounted for 17 (22%) patients. Since diffuse islet cell disease poses special problems in management, its prevalence is emphasized in this report. Among these patients with diffuse islet cell disease, there were 11 patients with adenomatosis, 4 with nesidioblastosis, and 2 with islet cell hyperplasia. Six of the 77 patients were found in multiple endocrine neoplasia, type I kindreds; diffuse islet cell disease was documented in 4 of these patients. We outline principles of management in patients with diffuse islet cell disease. Frozen section microscopy failed to identify nesidioblastosis or islet cell hyperplasia. Chez 77 malades, provenant de 2 centres médicaux, qui présentaient un hyperinsulinisme endogène, 17 cas de lésions diffuses des îlots de Langerhans ont été dénombrés. Ce fait est donc loin d'être exceptionnel et cette étude a pour but de le souligner. Parmi ces 17 malades, 11 présentaient des adénomes multiples (adénomatoses), 4 des nésidoblastomes (anomalies tissulaires multifocales), 2 des hyperplasies cellulaires insulaires. Chez ces 77 malades, 6 cas de MEN type I furent individualisés, 4 d'entre eux présentaient une maladie insulaire diffuse. Les auteurs, forts de cette expériences insistent sur les principes du traitement de ce type d'affection. Ils insistent sur le fait que l'étude histologique extemporanée ne permet pas d'identifier les nésidoblastomes et les hyperplasies cellulaires insulaires et que dans 70%–80% des cas les résections pancréatiques ne permettent pas d'obtenir la guérison. Un problema constante para el cirujano que opera pacientes con hiperinsulinismo endógeno es el de qué hacer cuando no se encuentre patología en el curso de la operación una vez realizada la exploración preliminar del páncreas. Los adenomas solitarios de células beta pueden pasar desapercibidos cuando no son palpables; la identificación de la enfermedad difusa de las células insulares plantea muchos problemas. Reconocemos tres alteraciones principales de tipo difuso: adenomatosis de células beta, nesidioblastosis e hiperplasia pancreática de células beta. Además, múltiples macroadenomas pueden coexistir o no con microadenomatosis o con hiperplasia en ciertos pacientes con hiperinsulinismo. Los desórdenes de células insulares de tipo multifocal son particularmente frecuentes en pacientes con Neoplasia Endocrina Multiple Tipo I.en_US
dc.format.extent502692 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherSpringer-Verlag; Springer Internationalen_US
dc.subject.otherMedicine & Public Healthen_US
dc.subject.otherGeneral Surgeryen_US
dc.subject.otherAbdominal Surgeryen_US
dc.subject.otherCardiac Surgeryen_US
dc.subject.otherThoracic Surgeryen_US
dc.subject.otherVascular Surgeryen_US
dc.subject.otherTraumatic Surgeryen_US
dc.titlePrevalence of diffuse pancreatic beta islet cell disease with hyperinsulinism: Problems in recognition and managementen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelSurgery and Anesthesiologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartments of Surgery, Internal Medicine (Endocrinology), and Pathology, The Milton S. Hershey Medical Center, USA; The Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA; Departments of Internal Medicine (Division of Endocrinology and Metabolism) and Surgery, The University of Michigan Medical Center, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationumDepartments of Surgery, Internal Medicine (Endocrinology), and Pathology, The Milton S. Hershey Medical Center, USA; The Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA; Departments of Internal Medicine (Division of Endocrinology and Metabolism) and Surgery, The University of Michigan Medical Center, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationumDepartments of Surgery, Internal Medicine (Endocrinology), and Pathology, The Milton S. Hershey Medical Center, USA; The Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA; Departments of Internal Medicine (Division of Endocrinology and Metabolism) and Surgery, The University of Michigan Medical Center, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationumDepartments of Surgery, Internal Medicine (Endocrinology), and Pathology, The Milton S. Hershey Medical Center, USA; The Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA; Departments of Internal Medicine (Division of Endocrinology and Metabolism) and Surgery, The University of Michigan Medical Center, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationumDepartments of Surgery, Internal Medicine (Endocrinology), and Pathology, The Milton S. Hershey Medical Center, USA; The Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA; Departments of Internal Medicine (Division of Endocrinology and Metabolism) and Surgery, The University of Michigan Medical Center, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationumDepartments of Surgery, Internal Medicine (Endocrinology), and Pathology, The Milton S. Hershey Medical Center, USA; The Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA; Departments of Internal Medicine (Division of Endocrinology and Metabolism) and Surgery, The University of Michigan Medical Center, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationumDepartments of Surgery, Internal Medicine (Endocrinology), and Pathology, The Milton S. Hershey Medical Center, USA; The Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA; Departments of Internal Medicine (Division of Endocrinology and Metabolism) and Surgery, The University of Michigan Medical Center, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid6148809en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/41314/1/268_2005_Article_BF01654942.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1007/BF01654942en_US
dc.identifier.sourceWorld Journal of Surgeryen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.